Table 3. Boceprevir labels (US and Europe).

Patients	HCV RNA		Treatment
	Week 4	Week 12
Boceprevir is administered after 4 weeks of “lead-in” with pegylated IFN-α and ribavirin alone at the dose of 800 mg every 7-9 hours with food, in combination with either pegylated IFN-α2b (1.5 μg/kg/week subcutaneously) or pegylated IFN-α2a (180 μg/week subcutaneously), and ribavirin (0.8 to 1.4 g/day according to body weight). Futility rule: stop therapy if HCV RNA >100 IU/mL at week 12 or detectable at week 24. Abbreviations: IFN, interferon.
Treatment-naïve without cirrhosis	Undetectable	Undetectable	Treat with 3 drugs until week 28
	Detectable	Undetectable	Treat with 3 drugs until week 36 Continue with pegylated IFN-α and ribavirin until week 48
Responder-relapsers and partial responders without cirrhosis	Undetectable	Undetectable	US: Treat with 3 drugs until week 36 Europe: Treat with 3 drugs until week 36 Continue with pegylated IFN-α and ribavirin until week 48
	Detectable	Undetectable	Treat with 3 drugs until week 36 Continue with pegylated IFN-α and ribavirin until week 48
Null responders and all cirrhotics	All patients		Treat with 3 drugs until week 48